RxDoctor Payments Data

Elizabeth Tree-Levasseur

Family Medicine · Whitehall, MINPI 1194716878

Payments from drug & device makers

$3,573in general payments, 2019–2025

Across 292 payments — averaging $12.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$527
  • GSK$418
  • AstraZeneca$359
  • Pfizer$313
  • Boehringer Ingelheim$265
  • Lilly USA, LLC$254
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,47097%
  • Education$1043%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,573 in reported general payments places this provider in the 85th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin200$186,810
EliquisApixaban131$128,950
TrulicityDulaglutide79$93,775
OzempicSemaglutide77$90,890
MounjaroTirzepatide80$85,236
XareltoRivaroxaban37$44,178
MyrbetriqMirabegron41$33,191
Tresiba Flextouch U-200Insulin Degludec13$26,808
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog30$25,603
Stiolto RespimatTiotropium Br/Olodaterol Hcl35$25,274
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$24,063
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog22$21,091
VraylarCariprazine Hcl15$20,185
Bydureon BciseExenatide Microspheres21$18,853
RexultiBrexpiprazole11$15,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$265$221,138247 claims
Lilly USA, LLCTrulicity, Mounjaro$254$179,011159 claims
PfizerEliquis$313$128,950131 claims
Novo NordiskOzempic$527$90,89077 claims
Johnson & JohnsonXarelto$24$44,17837 claims
GSKTrelegy Ellipta, Breo Ellipta$418$38,83655 claims
AbbVieVraylar, Linzess, Synthroid$151$38,102116 claims
Astellas Pharma US IncMyrbetriq$155$33,19141 claims
AstraZenecaFarxiga, Symbicort$359$25,09139 claims
MerckJanuvia, Verquvo$172$22,55737 claims
Otsuka America Pharmaceutical, Inc.Rexulti$66$15,56511 claims
NovartisEntresto$178$14,32422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Whitehall

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →